Xie, Z.-B., Wang, X.-B., Peng, Y.-C., Zhu, S.-L., Ma, L., Xiang, B.-D., Gong, W.-F., Chen, J., You, X.-M., Jiang, J.-H., Li, L.-Q. and Zhong, J.-H. (2014) Systematic Review Comparing the Safety and Efficacy of Conventional and Drug-Eluting-Bead Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma. Hepatology Research, 45, 190-200.

has been cited by the following article:

• TITLE: Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads

  AUTHORS: Natália Sousa Freitas Queiroz, Luciana Kikuchi, Regis Otaviano Franca Bezerra, Regiane S. S. M. Alencar, Aline Lopes Chagas, Cláudia Megumi Tani, Márcio Augusto Diniz, Aline Cristine Barbosa Santos, Airton Mota Moreira, Manoel de Souza Rocha, Luiz Augusto Carneiro D’Albuquerque, Francisco César Carnevale, Flair José Carrilho

  KEYWORDS: Hepatocellular Carcinoma, mRECIST Criteria, Transarterial Chemoembolization, Overall Survival, Drug-Eluting Beads

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.13, December 2, 2015

  ABSTRACT: Introduction: Transarterial chemoembolization (TACE) reduces tumor growth and increases survival in patients with hepatocellular carcinoma (HCC). Drug-eluting beads (DEB) deliver slow-release chemotherapy and reduce systemic toxicity during TACE. This study correlated initial tumor response according to modified RECIST (mRECIST) criteria and 1-year survival in patients with HCC treated with TACE-DEB, and identified predictors of tumor response. Methods: Fifty-two patients with HCC received TACE-DEB loaded with doxorubicin 75 mg during a 6-month period. Tumor response was evaluated 1 month after the procedure according to mRECIST criteria. Results: Most patients were cirrhotic and etiology of liver disease was hepatitis C in 26/52 (50%). Similar numbers of patients had Barcelona Clinic Liver Cancer (BCLC) A and BCLC B disease. Most patients had one nodule (66%). Complete response (CR) was achieved in 12/52 (23%), partial response in 19/52 (37%), stable disease in 4/52 (8%) and progressive disease in 17/52 (32%). Largest HCC ≤58 mm and BCLC stage A were associated with CR. The 1-year survival was 74%, with survival rates of 95% and 56% in the BCLC A and B groups, respectively. Variables reflecting tumor extension were associated with better survival. CR according to mRECIST criteria was a predictor of better 1-year survival (100% vs. 64%, P studies are needed to evaluate other predictors of survival and to determine if tumor response predicts long-term survival.